Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Oncologic Potential Endorsed By FDA, Bristol During House Hearing

Executive Summary

ImClone's oncologic agent Erbitux is "an active anticancer agent," Bristol-Myers Squibb and FDA Oncologic Drug Products Division Director Richard Pazdur, MD, agreed during a June 13 Energy & Commerce/Oversight Subcommittee hearing

You may also be interested in...



FDA Oncology Reviews Could Remain Split After CBER/CDER Reorganization

FDA is understood to be considering the creation of two divisions within the Center for Drug Evaluation & Research to review oncologic products as part of the CBER/CDER reorganization

FDA Oncology Reviews Could Remain Split After CBER/CDER Reorganization

FDA is understood to be considering the creation of two divisions within the Center for Drug Evaluation & Research to review oncologic products as part of the CBER/CDER reorganization

CBER Reorganization Will Proceed Without Siegel; OTRR Director To Retire

CBER Office of Therapeutics Review & Research Director Jay Siegel, MD, is the first high level departure from the agency since the announcement of the reorganization of the Center for Biologics Evaluation & Research

Related Content

UsernamePublicRestriction

Register

PS040010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel